Viemed Healthcare (VMD) AI Stock Analysis

Viemed Healthcare

(NASDAQ:VMD)

Select Model

Rating:71Outperform

Price Target:$11.00▲(13.75% Upside)

Action:reiterated

Date:08/21/26

Viemed's overall score is driven primarily by its exceptional fundamental profile, characterized by robust top-line growth, a pristine balance sheet, and a strong earnings report that yielded raised revenue guidance. These significant strengths are partially offset by a severe near-term technical downtrend and modest margin compression caused by a shifting revenue mix. Despite poor price momentum, the underlying cash generation and scalable operations provide a highly secure foundation for long-term growth.

Positive Factors

Revenue and Patient GrowthStrong revenue growth alongside a record ventilator patient base indicates expanding adoption of Viemed’s home respiratory model. Continued patient additions and improved usage compliance can support recurring therapy revenue and reinforce the company’s clinical position over the next several quarters.

Negative Factors

Margin CompressionLower adjusted EBITDA and gross margins indicate that revenue growth is not translating fully into operating profit. Although some effects were nonrecurring, persistent margin pressure would reduce cash available for reinvestment and could limit the earnings benefit of continued expansion.

Viemed Healthcare (VMD) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $368.31M
Dividend Yield: ―
Average Volume (3M): 328.00K
Price to Earnings (P/E): 25.6
Beta (1Y): 0.50
Revenue Growth: 25.21%
EPS Growth: 6.14%
Country: US
Employees: 1,438
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

Viemed Healthcare Business Overview & Revenue Model

Company Description

Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chroni...

How the Company Makes Money

Viemed primarily makes money by providing home-based respiratory therapy solutions that combine durable medical equipment (DME) with ongoing clinical and support services, and then billing third-party payors for those products and services. Its core...

Viemed Healthcare Earnings Call Summary

Earnings Call Date:Aug 02, 2026(Q2-2026)|% Change Since:-17.28%|Next Earnings Date:Nov 03, 2026

Earnings Call SentimentPositive

The call presented multiple material operational and financial positives: record revenue, the largest-ever active ventilator patient base, strong sequential and year-over-year growth in sleep and resupply, improving compliance, improved cash generation, and clear investments in technology and scalability (e.g., Tenor). Offsetting these were margin pressures in adjusted EBITDA and gross margin driven by revenue mix shifts, temporary maternal health transition costs, higher SG&A from deliberate scaling and one-time duplicative costs, and some near-term uncertainty on RT capacity. Management communicated confidence in the growth trajectory, provided constructive explanations for margin dynamics, and raised revenue guidance while outlining levers for second-half operating leverage.

Positive Updates

Record Quarterly Revenue and Raised Guidance

Revenue reached $78.1M in Q2, up ~24% year-over-year and ~4% sequentially. Management raised the low end of full-year net revenue guidance to $314M–$320M (from $312M–$320M).

Negative Updates

Adjusted EBITDA Margin Pressure

Adjusted EBITDA was $13.7M in Q2 (margin ~17.6%) versus ~22.7% in the prior-year quarter. Management noted a ~ $1.2M swing due to nonrecurring prior-year equipment disposal gains; excluding that, adjusted EBITDA increased year-over-year, but margin compression remains visible in H1.

Company Guidance

Management raised full‑year 2026 revenue guidance to $314–$320 million (from $312–$320M), narrowed adjusted EBITDA to $64–$68 million (from $65–$69M), and lowered net CapEx guidance to 8.5–10.0% of revenue (from 9–10.5%), while calling for continued sequential growth through H2 and an adjusted EBITDA margin of at least 20%; they emphasized generating solid free cash flow (H1 FCF $11.2M, trailing‑12M FCF $34.4M), funding ongoing growth, and preserving balance‑sheet flexibility after repaying about $2.2M of debt, repurchasing ~531,000 shares for $5.1M and ending June with $10.7M in cash (more cash than total debt).

Viemed Healthcare Financial Statement Overview

Summary

Viemed demonstrates a highly robust financial profile with sustained double-digit revenue expansion, accelerating operating cash flows, and an exceptionally conservative balance sheet. While there is minor margin compression, it is heavily outweighed by the firm's virtually debt-free capital structure and excellent top-line momentum.

Income Statement

82Very Positive

Balance Sheet

88Very Positive

Cash Flow

85Very Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	301.61M	270.28M	224.26M	183.01M	138.83M	117.06M
Gross Profit	172.55M	155.46M	133.20M	112.78M	84.68M	73.41M
EBITDA	53.62M	51.56M	42.31M	36.68M	24.82M	24.13M
Net Income	14.50M	14.93M	11.27M	10.24M	6.22M	9.13M
Balance Sheet
Total Assets	204.22M	214.94M	177.07M	154.90M	117.04M	117.96M
Cash, Cash Equivalents and Short-Term Investments	10.68M	13.50M	17.54M	12.84M	16.91M	28.41M
Total Debt	11.60M	15.95M	6.87M	10.32M	694.00K	6.52M
Total Liabilities	58.26M	71.42M	43.77M	41.00M	19.95M	23.14M
Stockholders Equity	144.03M	141.54M	131.39M	113.89M	97.09M	94.82M
Cash Flow
Free Cash Flow	29.24M	11.93M	1.32M	19.12M	4.85M	2.75M
Operating Cash Flow	60.78M	51.92M	39.09M	45.21M	27.75M	22.49M
Investing Cash Flow	-53.23M	-50.17M	-30.70M	-52.11M	-23.98M	-19.75M
Financing Cash Flow	-16.89M	-5.79M	-3.69M	2.83M	-15.27M	-5.32M

Viemed Healthcare Technical Analysis

Technical Analysis SentimentPositive

Last Price9.67

Price Trends

50DMA9.23Positive

100DMA10.10Negative

200DMA9.57Positive

Market Momentum

MACD0.16Negative

RSI53.11Neutral

STOCH58.28Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VMD, the sentiment is Positive. The current price of 9.67 is above the 20-day moving average (MA) of 9.64, above the 50-day MA of 9.23, and above the 200-day MA of 9.57, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 53.11 is Neutral, neither overbought nor oversold. The STOCH value of 58.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VMD.

Viemed Healthcare Risk Analysis

Viemed Healthcare disclosed 39 risk factors in its most recent earnings report. Viemed Healthcare reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Viemed Healthcare Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

VMD against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TCMD	81Outperform	$521.91M	21.14	11.49%	―	17.22%	74.89%
BVS	71Outperform	$1.12B	16.59	28.39%	―	3.14%	―
VMD	71Outperform	$368.31M	25.64	10.30%	―	25.21%	6.14%
INGN	55Neutral	$182.05M	-7.62	-13.17%	―	3.15%	14.61%
OM	53Neutral	$75.67M	-0.98	-62.25%	―	-1.26%	79.82%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SENS	43Neutral	$502.83M	-4.19	-165.83%	―	90.63%	-11.42%

* Healthcare Sector Average

Performance Comparison

VMD and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
VMD	Viemed Healthcare US	9.67	3.10	47.18%
INGN	Inogen Inc	6.86	-1.35	-16.44%
SENS	Senseonics Holdings Inc.	9.51	2.63	38.23%
TCMD	Tactile Systems Technology	23.04	7.27	46.10%
OM	Outset Medical, Inc.	4.03	-8.98	-69.02%
BVS	Bioventus, Inc.	13.32	6.76	103.13%

Viemed Healthcare Corporate Events

Business Operations and StrategyRegulatory Filings and Compliance

Viemed Healthcare Updates Investor Deck, Highlights Growth Strategy

Positive

Aug 20, 2026

Viemed Healthcare has released an updated investor deck dated August 2026, which it plans to use in presentations to investors, analysts and other stakeholders, and has made the materials available on its website. The presentation, framed as summary...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 20, 2026

Viemed Healthcare AI Stock Analysis